COVID-19 Vaccines and Vaccination

A section of Vaccines (ISSN 2076-393X).

Section Information

Aims

The aim of this “COVID-19 vaccines and vaccination” special issue is to provide with information on currently available and novel experimental approaches for the development of vaccines for the control of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and it associated coronavirus disease 2019 (COVID-19).

Scope

Global efforts to develop vaccines recently have resulted in 3 FDA-approved vaccines candidates with excellent safety and efficacy profiles in human clinical trials that have resulted in large-scale vaccination campaigns early in 2021.Currently, RNA-based vaccines and replication defective adenovirus-based vector have been used for the treatment of COVID-19 in humans. However, additional safe and effective vaccines are needed for the treatment of SARS-CoV-2 infection and its associated COVID-19 disease. 

In this section “COVID-19 vaccines and vaccination” we will consider original research and review articles, including short reports and full-size manuscripts, covering aspects related to SARS-CoV-2 vaccine development for the treatment of COVID-19 disease. These include (but not limited to) antigen selection; subunit, inactivated, and live-attenuated vaccines; approaches to enhance innate and adaptive B- and T-cell protective responses; vaccine adjuvants; delivery methods and strategies; immunological responses to SARS-CoV-2 infection or COVID-19 disease; and animal models to assess protection efficacy against SARS-CoV-2 infection and COVID-19 disease.

 

Editorial Board

Special Issues

Following special issues within this section are currently open for submissions:

Papers Published

Back to TopTop